Second-generation tracers, including [18F]-PI-2620 and [18F]-PM-PBB3, have demonstrated improved specificity and efficacy in detecting tau pathology in PSP and CBD, overcoming some of the limitations observed with earlier tracers. The gene discussed is MAPT; the disease is red-green color blindness.